If you have been reading about Selank and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-31. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
== External links == Target+Peptide at the U.S. National Library of Medicine Medical Subject Headings (MeSH) SPdb (Signal Peptide DataBase) Archived 2016-01-22 at the Wayback Machine Prediction methods: SignalP — predicts the presence and location of signal peptide cleavage sites in amino acid sequences from all domains of organisms. PHOBIUS - combined transmembrane topology and signal peptide predictor
In 1857, French microbiologist Louis Pasteur showed that by bubbling oxygen into the yeast broth, cell growth could be increased, but fermentation was inhibited – an observation later called the "Pasteur effect". In the paper "Mémoire sur la fermentation alcoolique," Pasteur proved that alcoholic fermentation was conducted by living yeasts and not by a chemical catalyst. By the late 18th century two yeast strains used in brewing had been identified: Saccharomyces cerevisiae (top-fermenting yeast) and S. pastorianus (bottom-fermenting yeast). S. cerevisiae has been sold commercially by the Dutch for bread-making since 1780; while, around 1800, the Germans started producing S. cerevisiae in the form of cream. In 1825, a method was developed to remove the liquid so the yeast could be prepared as solid blocks. The industrial production of yeast blocks was enhanced by the introduction of the filter press in 1867. In 1872, Baron Max de Springer developed a manufacturing process to create granulated yeast from beetroot molasses, a technique that was used until the first World War. In the United States, naturally occurring airborne yeasts were used almost exclusively until commercial yeast was marketed at the Centennial Exposition in 1876 in Philadelphia, where Charles L. Fleischmann exhibited the product and a process to use it, as well as serving the resultant baked bread.
Kidder had a central supporting role in the airplane-themed drama The Great Waldo Pepper (1975) opposite Robert Redford and Susan Sarandon, followed by a lead role in the psychological horror film The Reincarnation of Peter Proud, directed by J. Lee Thompson, in which she portrayed a woman about whom a college professor has recurring nightmares. Variety praised her performance in the latter film as "outstandingly rich." In the summer of 1975, Kidder was hired to direct a documentary short chronicling the making of The Missouri Breaks (1976), a Western film starring Marlon Brando and Jack Nicholson. "I was such a jerk," she recalled. "I mean, I thought they wanted a real documentary. So, I filmed all the behind-the-scenes rows and arguments and shot footage of the vet shooting up the horses with tranquilizers so the actors would look as if they rode well. What an idiot I was. Then when they fired me, I realized what they'd wanted was a publicity film." She subsequently co-starred with Peter Fonda in 92 in the Shade, also in 1975, a drama directed by novelist Thomas McGuane, based on his own book. Kidder then took a hiatus from acting, though she appeared in the March 9, 1975, edition of The American Sportsman, learning how to hang glide, and providing the narration, with a remote microphone recording her reactions in flight; the segment concluded with Kidder doing solos soaring amid the Wyoming Rockies. She was also photographed by Douglas Kirkland for the March 1975 issue of Playboy, accompanied by an article written by Kidder herself.
Sources: en.wikipedia.org
== Limitations == FFF does not work for small molecules, because of their fast diffusion. For an effective separation, the sample has to be concentrated very close to the accumulation wall (a distance less than 10 μm), which requires the drift velocity caused by the force field to be two orders of magnitude higher compared to the diffusion coefficient. The maximum field strength which can be generated in an FFF channel determines the lower size range of separation. For current instrumentation this is approximately 1 nm. Although FFF is an extremely versatile technique, there is no "one size fits all" method for all applications. Different FFF methods need specialized instrumentation. Currently only the so-called asymmetric flow field-flow fractionation (AF4) has gained widespread use. Other methods like centrifugal, thermal or electrical FFF still have a niche existence. FFF behaves differently from column chromatography and can be counter-intuitive for HPLC or SEC users. Understanding of the working principle of FFF is vital for a successful application of the method.
Brain cells make up the functional tissue of the brain. The rest of the brain tissue is the structural stroma that includes connective tissue such as the meninges, blood vessels, and ducts. The two main types of cells in the brain are neurons, also known as nerve cells, and glial cells, also known as neuroglia. There are many types of neuron, and several types of glial cell. Neurons are the excitable cells of the brain that function by communicating with other neurons and interneurons (via synapses), in neural circuits and larger brain networks. The two main neuronal classes in the cerebral cortex are excitatory projection neurons (around 70-80%) and inhibitory interneurons (around 20–30%). Neurons are often grouped into a cluster known as a nucleus where they usually have roughly similar connections and functions. Nuclei are connected to other nuclei by tracts of white matter. Glia are the supporting cells of the neurons and have many functions of which not all are clearly understood, but include providing support and nutrients to the neurons. Glia are grouped into macroglia—astrocytes, ependymal cells, and oligodendrocytes, and much smaller microglia which are the macrophages of the central nervous system. Astrocytes are capable of communication with neurons involving a signaling process similar to neurotransmission, called gliotransmission.
== History == In 1935, David Shakarian, an Armenian-American businessman, opened a small health food store originally named Lackzoom, in downtown Pittsburgh. He made US$35 on his first day and was able to open a second store within six months. Despite initial setbacks, such as the Ohio River flooding into downtown on St. Patrick's Day that wiped out both stores in 1936, Shakarian persevered and reopened the next year. He later expanded into mail-order sales of health foods, vitamins, and prescription drugs, capitalizing on the growing interest in physical fitness and health consciousness during the 1960s. In the 1960s, the company changed the name of its stores to General Nutrition Centers. Shakarian stepped down as chief executive officer in February 1984 but continued as chairman until his death later that year. Shakarian took GNC public (listed on the NYSE) in the 1980s. Gary Daum was named chief executive office in February 1984. In May 1985, Jerry Horn took on the role. GNC was taken private and sold to Thomas H. Lee Partners a PE investment/management fund in the late 1980s. Thomas Lee ran GNC and took it public prior to selling the company to Royal Dutch Numico and Numico acquired GNC in 1999; it sold GNC to Apollo Management in 2003. Ontario Teachers' Pension Plan and Ares Management bought GNC in 2007. GNC went public in 2011. In 1990, the company considered relocating but a public/private effort retained GNC headquarters in Downtown Pittsburgh.
In the US the first large-scale use of cement was Rosendale cement, a natural cement mined from a massive deposit of dolomite discovered in the early 19th century near Rosendale, New York. Rosendale cement was extremely popular for the foundation of buildings (e.g., Statue of Liberty, Capitol Building, Brooklyn Bridge) and lining water pipes. Sorel cement, or magnesia-based cement, was patented in 1867 by the Frenchman Stanislas Sorel. It was stronger than Portland cement but its poor water resistance (leaching) and corrosive properties (pitting corrosion due to the presence of leachable chloride anions and the low pH (8.5–9.5) of its pore water) limited its use as reinforced concrete for building construction. The next development in the manufacture of Portland cement was the introduction of the rotary kiln. It produced a clinker mixture that was both stronger, because more alite (C3S) is formed at the higher temperature it achieved (1450 °C), and more homogeneous. Because raw material is constantly fed into a rotary kiln, it allowed a continuous manufacturing process to replace lower capacity batch production processes.
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.